文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Examining heterogeneity in phase II trial designs may improve success in phase III.

作者信息

Tuma Rabiya S

出版信息

J Natl Cancer Inst. 2008 Feb 6;100(3):164-6. doi: 10.1093/jnci/djn006. Epub 2008 Jan 29.

DOI:10.1093/jnci/djn006
PMID:18230788
Abstract
摘要

相似文献

[1]
Examining heterogeneity in phase II trial designs may improve success in phase III.

J Natl Cancer Inst. 2008-2-6

[2]
Randomized phase II trials: misleading and unreliable.

J Clin Oncol. 2010-11-1

[3]
Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

J Clin Oncol. 2008-3-10

[4]
Criticism of tumor response criteria raises trial design questions.

J Natl Cancer Inst. 2006-2-15

[5]
Clinical trials of novel and targeted therapies: endpoints, trial design, and analysis.

Cancer Invest. 2008-6

[6]
Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.

Clin Cancer Res. 2006-4-1

[7]
Optimising the design of phase II oncology trials: the importance of randomisation.

Eur J Cancer. 2009-1

[8]
Newer phase II trial designs gaining ground.

J Natl Cancer Inst. 2007-10-3

[9]
Sorafenib in hepatocellular carcinoma: separating the hype from the hope.

J Clin Oncol. 2008-12-20

[10]
Early average change in tumor size in a phase 2 trial: efficient endpoint or false promise?

J Natl Cancer Inst. 2007-10-3

引用本文的文献

[1]
Quality of reporting in oncology phase II trials: A 5-year assessment through systematic review.

PLoS One. 2017-12-7

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索